Form 4: Xilio Therapeutics Director Yuan Xu Granted 31,000 Stock Options

Xilio Therapeutics, Inc. Director Yuan Xu has been granted 31,000 stock options with an exercise price of $0.693 per share, aligning executive incentives with shareholder value.

Summary

• Xilio Therapeutics, Inc. (XLO) Director Yuan Xu was granted 31,000 stock options on June 11, 2025.
• The exercise price for these options is $0.693 per share.
• The options are set to expire on June 10, 2035.
• The options will vest 100% on the earlier of June 11, 2026, or the Issuer's next annual meeting of stockholders following the grant date, contingent on Mr. Xu's continued service to the Issuer.

Sentiment

Score: 6

Explanation: The grant of stock options to a director is a positive step for corporate governance, as it aligns the director's financial interests with the long-term performance of the company and its shareholders. While not a direct financial performance indicator, it signals commitment and incentivization.

Positives

• The grant of stock options to Director Yuan Xu aligns his interests with those of the shareholders, incentivizing long-term company performance.
• The options have a 10-year expiration period, providing a long-term incentive horizon.

Future Outlook

The stock options granted to Director Yuan Xu are subject to a vesting schedule, with full vesting occurring on the earlier of June 11, 2026, or the company's next annual meeting of stockholders, provided his continued service.

Industry Context

This Form 4 filing details a routine insider transaction related to director compensation, which is a common practice across industries to align management and board interests with shareholder value. It does not provide broader insights into industry trends or competitive landscape.

Related Party Transactions

• Director Yuan Xu, a related party, received a grant of 31,000 stock options from Xilio Therapeutics, Inc. as part of his compensation.

Stakeholder Impact

• Shareholders: The grant of options could lead to minor dilution upon exercise but aims to align the director's incentives with long-term shareholder value creation.
• Employees: No direct impact on general employees is indicated by this filing.

Next Steps

• The granted stock options will vest on the earlier of June 11, 2026, or the Issuer's next annual meeting of stockholders, subject to continued service.

Key Dates

Keywords

Xilio Therapeutics, XLO, Stock Options, Director Compensation, Insider Transaction, SEC Form 4, Equity Grant, Yuan Xu